Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute inhaled fluticasone before AMP bronchial provocation in asthma and allergic rhinitis
ACTRN12605000611628Phase 4Completed
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Oct 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fluticasone in asthma and allergic rhinitis (AR) (2 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoint: Perception of dyspnoea during AMP bronchial provocative test. Started Oct 2005; status: completed.
02
Drugs
fluticasone
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on ACTRN12605000611628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000611628.